Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| GERN | GERON CORP | 2026-10-15 14:20:34 | 1.23 | 0.04 | 2.94 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GERN | 0000886744 | GERON CORP | US3741631036 | 549300T282D7Z2YESL90 | 752287752 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 919 EAST HILLSDALE BOULEVARD | FOSTER CITY | CA | 94404 | UNITED STATES | US | 6504737700 | 919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, 94404 | 919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, 94404 | GERON CORPORATION | Biotechnology | 1990 | Harout Semerjian | 82 | http://www.geron.com/ | 860,500,000 | 639,856,222 | 642,473,409 | Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase. | 2026-10-09 03:04:36 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 860,500,000 | -1,570,200,000 | -64.5987 | 640,544,661 | 3,640,191 | 0.5715 |
| 2024 | 2,430,700,000 | 1,036,154,000 | 74.3005 | 636,904,470 | 90,845,161 | 16.6365 |
| 2023 | 1,394,546,000 | 891,359,000 | 177.1427 | 546,059,309 | 37,336,823 | 7.3393 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Dawn C. Bir | Chief Executive Officer, President | 2025 | 318,190 | 0 | 0 | 0 | 40,258 | 522,122 |
| Michelle J. Robertson | Secretary, Executive Vice President, Chief Financial Officer, Treasurer | 2025 | 559,800 | 0 | 289,300 | 239,300 | 11,452 | 2,250,082 |
| Harout Semerjian | Chief Executive Officer, President | 2025 | 321,538 | 0 | 0 | 203,000 | 1,817 | 10,221,755 |
| John A. Scarlett, M.D. | Chief Executive Officer, President, Chairman Of The Board | 2025 | 309,781 | 0 | 1,078,300 | 0 | 1,726,569 | 7,422,754 |
| Ahmed Elnawawi | Chief Commercial Officer, Executive Vice President | 2025 | 107,692 | 200,000 | 0 | 0 | 242 | 2,881,334 |
| Fiscal Year | Employee Count |
|---|---|
| 2016 | 15 |
| 2015 | 17 |
| 2014 | 42 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | — | — | 237,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | 183,881,000 | 76,994,000 | 237,000 |
| Research And Development Expenses | 71,433,000 | 103,738,000 | 125,046,000 |
| General And Administrative Expenses | 159,256,000 | 145,732,000 | 69,135,000 |
| Operating Expenses | 252,466,000 | 250,726,000 | 194,181,000 |
| Operating Income | -68,585,000 | -173,732,000 | -193,944,000 |
| Net Income | -83,500,000 | -174,572,000 | -184,127,000 |
| Earnings Per Share Basic | -0.13 | -0.27 | -0.32 |
| Earnings Per Share Diluted | -0.13 | -0.27 | -0.32 |
| Weighted Average Shares Outstanding Basic | 666,662,989 | 646,033,247 | 570,645,405 |
| Weighted Average Shares Outstanding Diluted | 666,662,989 | 646,033,247 | 570,645,405 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 77,560,000 | 79,016,000 | 70,023,000 |
| Marketable Securities Current | — | 327,550,000 | 263,676,000 |
| Accounts Receivable | 36,987,000 | 35,946,000 | — |
| Inventories | 116,636,000 | 38,714,000 | — |
| Non Trade Receivables | 2,239,000 | 2,853,000 | 1,655,000 |
| Other Assets Current | 4,610,000 | 5,053,000 | 4,879,000 |
| Total Assets Current | 520,271,000 | 490,992,000 | 341,348,000 |
| Marketable Securities Non Current | — | 94,519,000 | 43,298,000 |
| Property Plant And Equipment | 884,000 | 1,310,000 | 1,177,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 50,269,000 | 102,789,000 | 52,728,000 |
| Total Assets | 570,540,000 | 593,781,000 | 394,076,000 |
| Accounts Payable | 11,257,000 | 8,595,000 | 6,161,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 3,110,000 | 2,186,000 | 46,893,000 |
| Other Liabilities Current | 51,340,000 | 35,549,000 | 40,308,000 |
| Total Liabilities Current | 111,542,000 | 88,298,000 | 108,070,000 |
| Long Term Debt | 119,547,000 | 118,476,000 | 35,051,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 233,126,000 | 225,163,000 | 38,057,000 |
| Total Liabilities | 344,668,000 | 313,461,000 | 146,127,000 |
| Common Stock | 640,000 | 606,000 | 545,000 |
| Retained Earnings | -1,855,841,000 | -1,772,341,000 | -1,597,769,000 |
| Accumulated Other Comprehensive Income | 269,000 | 261,000 | 185,000 |
| Total Shareholders Equity | 225,872,000 | 280,320,000 | 247,949,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 474,000 | 546,000 | 442,000 |
| Share Based Compensation Expense | 26,659,000 | 31,185,000 | 18,526,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 991,000 | 35,695,000 | — |
| Change In Inventories | 77,922,000 | 37,971,000 | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 2,661,000 | 2,435,000 | -4,029,000 |
| Change In Other Liabilities | 7,689,000 | 9,049,000 | 2,224,000 |
| Cash From Operating Activities | -111,037,000 | -218,618,000 | -167,743,000 |
| Purchases Of Marketable Securities | 304,421,000 | 476,932,000 | 475,594,000 |
| Sales Of Marketable Securities | 411,717,000 | 371,608,000 | 296,102,000 |
| Acquisition Of Property Plant And Equipment | — | 680,000 | 830,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 107,247,000 | -106,004,000 | -180,322,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 1,520,000 | 32,683,000 | 13,070,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 0 | 121,120,000 | 29,700,000 |
| Repayment Of Long Term Debt | 0 | 86,554,000 | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 2,267,000 | 334,372,000 | 362,021,000 |
| Change In Cash | -1,436,000 | 9,738,000 | 13,929,000 |
| Cash At End Of Period | 77,560,000 | 79,016,000 | 70,023,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 11,712,000 | 10,364,000 | -7,017,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.13 | -0.27 | -0.32 |
| Price To Earnings Ratio | -10.1538 | -13.1111 | -6.5938 |
| Earnings Growth Rate | -51.8519 | -15.625 | -13.5135 |
| Price Earnings To Growth Ratio | 0.1958 | 0.8391 | 0.4879 |
| Book Value Per Share | 0.3388 | 0.4339 | 0.4345 |
| Price To Book Ratio | 3.896 | 8.1584 | 4.8561 |
| Ebitda | -50,369,000 | -155,522,000 | -175,373,000 |
| Enterprise Value | 925,092,145.48 | 2,328,603,694.38 | 1,215,982,804.55 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.543 | 0.4304 | 0.3305 |
| Capital Expenditures | 48,000 | 679,000 | 826,000 |
| Free Cash Flow | -111,085,000 | -219,297,000 | -168,569,000 |
| Return On Equity | -0.3697 | -0.6228 | -0.7426 |
| One Year Beta | 1.1381 | 0.6129 | 1.4491 |
| Three Year Beta | 1.093 | 1.2051 | 1.2135 |
| Five Year Beta | 1.1267 | 0.9171 | 0.9765 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Spiegel Robert J. | Director | 2026-09-30 | 6,351 | A | 212,161 |
| Spiegel Robert J. | Director | 2026-06-30 | 6,103 | A | 205,810 |
| Bir Dawn Carter | Director | 2026-05-20 | 220,000 | A | 220,000 |
| McDonald John F | Director | 2026-05-20 | 220,000 | A | 220,000 |
| Molineaux Susan | Director | 2026-05-20 | 220,000 | A | 220,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Elmwood Wealth Management, Inc. | 2026-09-30 | 34,791 | 28,285 | 1.23 |
| Summit Financial Strategies, Inc. | 2026-09-30 | 33,210 | 27,000 | 1.23 |
| Summit Financial Strategies, Inc. | 2026-09-30 | 3,690 | 3,000 | 1.23 |
| Seelaus Asset Management LLC | 2026-09-30 | 15,375 | 12,500 | 1.23 |
| Allied Investment Advisors, LLC | 2026-09-30 | 19,630 | 15,959 | 1.23 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Pacer Funds Trust | 2026-07-31 | Pacer WealthShield ETF | PWS | 10,128 | 13,065.12 | 0.0543 |
| ETFis Series Trust I | 2026-07-31 | Virtus Biotech ETF | BBP | 1,180,129 | 1,522,366.41 | 1.5449 |
| VICTORY PORTFOLIOS III | 2026-07-31 | Victory Extended Market Index Fund | USMIX | 72,538 | 93,574.02 | 0.0116 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 746,889 | 963,486.81 | 0.0349 |
| Global X Funds | 2026-07-31 | Global X Russell 2000 ETF | RSSL | 267,254 | 344,757.66 | 0.0232 |